Alzamend Neuro Annual Report 2017

Alzamend Neuro, Inc. is a Delaware corporation formed in 2016 to develop and commercialize patented immunotherapy approaches for treating and preventing Alzheimer's disease. The company's novel therapeutic strategy differs from current FDA-approved Alzheimer's drugs by addressing the underlying immune system dysfunction rather than only treating symptoms.